Acrivon Therapeutics reported a net loss of $22.8 million for the fourth quarter of 2024 and $80.6 million for the full year 2024, compared to net losses of $19.3 million and $60.4 million for the respective periods in 2023. Research and development expenses increased to $18.6 million for Q4 2024 and $64.0 million for the full year, driven by the advancement of the ACR-368 registrational trial and the initiation of the ACR-2316 clinical trial.
The company provided updated positive data for ACR-368 in endometrial cancer patients, showing a 35% confirmed overall response rate (cORR) in OncoSignature-positive (BM+) patients who had progressed on prior anti-PD-1 and chemotherapy. This cORR was more than double the 15% observed in their last prior line of therapy. Specifically, BM+ patients who relapsed after prior therapy achieved a 50% cORR with a median duration of response exceeding 10 months.
Acrivon also reported progress for ACR-2316, with enrollment completed in the first three dose-escalation cohorts of its Phase 1 trial. Initial clinical activity, including tumor shrinkage, was observed at dose level three. As of December 31, 2024, the company had $184.6 million in cash, cash equivalents, and investments, extending its projected cash runway into 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.